Clinical Report: Effective Use of Telitacicept in Managing IgA Nephropathy
Overview
This case study presents a 47-year-old male with stage 4 chronic kidney disease and IgA nephropathy treated with telitacicept. After 18 months of treatment, improvements were observed in proteinuria and estimated glomerular filtration rate (eGFR).
Background
IgA nephropathy (IgAN) is a prevalent form of primary glomerulonephritis that can lead to renal failure, necessitating renal replacement therapy. Current treatments for IgAN are limited, particularly for patients with advanced chronic kidney disease. Telitacicept, an APRIL and BAFF inhibitor, has shown potential in managing IgAN, but its efficacy in patients with severe kidney impairment requires further investigation.
Data Highlights
Parameter
Before Treatment
After Treatment
Proteinuria (g/day)
2.82
0.60
eGFR (mL/min/1.73 m²)
26.95
35.69
Serum Albumin
Decreased
Increased
Hematuria
Not specified
Decreased
Key Findings
The patient showed a reduction in proteinuria from 2.82 g/day to 0.60 g/day after treatment with telitacicept.
eGFR improved from 26.95 to 35.69 mL/min/1.73 m² over 18 months.
Serum albumin levels increased during the treatment period.
No infections or adverse events were reported during the treatment with telitacicept.
Immunoglobulin and lymphocyte levels decreased, while inflammatory markers remained stable.
Clinical Implications
Further research is warranted to confirm these results and explore the applicability of telitacicept in this patient population.
Conclusion
This case highlights the use of telitacicept in managing IgAN in a patient with stage 4 chronic kidney disease.
In a randomized crossover trial of insulin-treated patients receiving hemodialysis, real-time continuous glucose monitoring did not improve the primary hypoglycemia outcome but increased time in range and reduced time above range vs capillary testing.
